Analysts have lowered their sales estimates for Ipsen’s late-stage pipeline asset palovarotene after the US Food and Drug Administration imposed a clinical hold on testing the rare bone disorder candidate in children below 14 years of age, on safety concerns.
Ipsen’s Palovarotene Hit By FDA Clinical Hold
Analysts Cut Their Palovarotene Sales Projections
The US FDA has slapped a partial clinical hold on Ipsen’s palovarotene clinical trials in rare bone disorders in children less than 14 years old, due to bone growth concerns.
